Completed PHASE1 INTERVENTIONAL 2-arm NCT04493281

Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects

Sponsor: Tanabe Pharma Corporation

Updated 8 times since 2020 Last updated: Dec 15, 2025 Started: Mar 22, 2019 Primary completion: Apr 21, 2019 Completion: May 9, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy Adult Subjects, this trial is completed. The trial is conducted by Tanabe Pharma Corporation and has accumulated 8 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE1
Jan 2026 — Feb 2026 [monthly]

Completed PHASE1
Sep 2024 — Jan 2026 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Feb 2024 — Jul 2024 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jan 2021 — Feb 2024 [monthly]

Completed PHASE1
Sep 2020 — Jan 2021 [monthly]

Completed PHASE1
Aug 2020 — Sep 2020 [monthly]

Completed PHASE1

First recorded

Mar 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tanabe Pharma Corporation

Data source: Tanabe Pharma Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tokyo, Japan